354 related articles for article (PubMed ID: 34573278)
1. Non-Coding RNA in Systemic Sclerosis: A Valuable Tool for Translational and Personalized Medicine.
Rusek M; Krasowska D
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573278
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion.
Servaas NH; Mariotti B; van der Kroef M; Wichers CGK; Pandit A; Bazzoni F; Radstake TRDJ; Rossato M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922041
[TBL] [Abstract][Full Text] [Related]
3. The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis.
Mariotti B; Servaas NH; Rossato M; Tamassia N; Cassatella MA; Cossu M; Beretta L; van der Kroef M; Radstake TRDJ; Bazzoni F
Front Immunol; 2019; 10():100. PubMed ID: 30804934
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of long noncoding RNAs ANCR, TINCR, HOTTIP and SPRY4-IT1 in plasma of systemic sclerosis patients: SPRY4-IT1 as a novel biomarker of scleroderma and its subtypes.
Abd-Elmawla MA; Hassan M; Elsabagh YA; Alnaggar ARLR; Senousy MA
Cytokine; 2020 Sep; 133():155124. PubMed ID: 32442909
[TBL] [Abstract][Full Text] [Related]
5. The Roles of Noncoding RNAs in Systemic Sclerosis.
Liu Y; Cheng L; Zhan H; Li H; Li X; Huang Y; Li Y
Front Immunol; 2022; 13():856036. PubMed ID: 35464474
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of epigenetics in systemic sclerosis pathogenesis.
Ciechomska M; van Laar JM; O'Reilly S
Genes Immun; 2014 Oct; 15(7):433-9. PubMed ID: 25030429
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine in systemic sclerosis: facts and promises.
Dobrota R; Mihai C; Distler O
Curr Rheumatol Rep; 2014 Jun; 16(6):425. PubMed ID: 24752884
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology of systemic sclerosis.
Thoreau B; Chaigne B; Renaud A; Mouthon L
Presse Med; 2021 Apr; 50(1):104087. PubMed ID: 34718115
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.
Tsai CY; Hsieh SC; Wu TH; Li KJ; Shen CY; Liao HT; Wu CH; Kuo YM; Lu CS; Yu CL
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349208
[TBL] [Abstract][Full Text] [Related]
11. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics-integrated screening of systemic sclerosis-specific expressed markers to identify therapeutic targets.
Jin J; Liu Y; Tang Q; Yan X; Jiang M; Zhao X; Chen J; Jin C; Ou Q; Zhao J
Front Immunol; 2023; 14():1125183. PubMed ID: 37063926
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic roles of B lymphocytes in systemic sclerosis.
Yoshizaki A
Immunol Lett; 2018 Mar; 195():76-82. PubMed ID: 29307688
[TBL] [Abstract][Full Text] [Related]
14. Genetics of scleroderma: implications for personalized medicine?
Assassi S; Radstake TR; Mayes MD; Martin J
BMC Med; 2013 Jan; 11():9. PubMed ID: 23311619
[TBL] [Abstract][Full Text] [Related]
15. Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis.
Messemaker TC; Chadli L; Cai G; Goelela VS; Boonstra M; Dorjée AL; Andersen SN; Mikkers HMM; van 't Hof P; Mei H; Distler O; Draisma HHM; Johnson ME; Orzechowski NM; Simms RW; Toes REM; Aarbiou J; Huizinga TW; Whitfield ML; DeGroot J; de Vries-Bouwstra J; Kurreeman F
J Invest Dermatol; 2018 Apr; 138(4):826-835. PubMed ID: 29179949
[TBL] [Abstract][Full Text] [Related]
16. New insights into the genetics and epigenetics of systemic sclerosis.
Angiolilli C; Marut W; van der Kroef M; Chouri E; Reedquist KA; Radstake TRDJ
Nat Rev Rheumatol; 2018 Nov; 14(11):657-673. PubMed ID: 30305700
[TBL] [Abstract][Full Text] [Related]
17. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.
Tsou PS
Curr Rheumatol Rep; 2019 Dec; 21(12):69. PubMed ID: 31813068
[TBL] [Abstract][Full Text] [Related]
19. Unfolding the pathogenesis of scleroderma through genomics and epigenomics.
Tsou PS; Sawalha AH
J Autoimmun; 2017 Sep; 83():73-94. PubMed ID: 28526340
[TBL] [Abstract][Full Text] [Related]
20. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.
Yoshizaki A
J Dermatol; 2016 Jan; 43(1):39-45. PubMed ID: 26782005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
